心可舒治疗冠心病PCI术后焦虑抑郁的临床疗效

摘要

目的 观察心可舒治疗冠心病PCI术后合并焦虑抑郁的疗效.方法 选择福建中医药大学附属人民医院心内科住院及门诊冠心病经皮冠状动脉介入治疗(PCI)术后焦虑抑郁病人63例为研究对象,随机分为心可舒组和黛力新组,在西医规范治疗基础上分别联合心可舒和黛力新治疗.观察两组治疗前后汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)评分,分析比较治疗前后组间及组内差异,检验心可舒对该病的疗效是否优于黛力新.结果 心可舒组和黛力新组HAMA、HAMD积分治疗后较治疗前均有明显降低,组内对比差异有统计学意义(P ＜0.001).对心可舒组和黛力新组治疗前后HAMA、HAMD积分进行非劣效性检验,心可舒组非劣于黛力新组(P＜ 0.001).结论 心可舒可显著改善冠心病PCI术后病人焦虑抑郁症状,且疗效非劣于黛力新.%Objective To observe the effect of Xinkeshu tablet in the treatment of anxiety and depression with coronary heart disease after percutaneous coronary intervention (PCI).Methods Sixty-three patients with anxiety and depression after PCI were selected as research object,and divided into Xinkeshu tablet group,and deanxit group,treated with Xinkeshu tablet and deanxit respectively.Hamilton Anxiety Scale (HAMA) and Hamilton depression scale(HAMD) scores were observed before and after treatment.Results After treatment,the scores of HAMA and HAMD were lower in two groups (P ＜0.001).The efficacy in Xinkeshu tablet group was as that as in deanxit group (P ＜0.001).Conclusion Xinkeshu tablet can significantly improve the symptoms of anxiety and depression in patients with anxiety and depression after PCI,and the curative effect is same as deanxit.